CAPR

Capricor Therapeutics (CAPR) Price Target Increased by 16.42% to 26.52

The average one-year price target for Capricor Therapeutics (NASDAQ:CAPR) has been revised to 26.52 / share. This is an increase of 16.42% from the prior estimate of 22.78 dated October 4, 2023.

The price target is an average of many targets provided by analysts. The latest targets range from a low of 12.12 to a high of 42.00 / share. The average price target represents an increase of 840.43% from the latest reported closing price of 2.82 / share.

What is the Fund Sentiment?

There are 52 funds or institutions reporting positions in Capricor Therapeutics. This is an increase of 2 owner(s) or 4.00% in the last quarter. Average portfolio weight of all funds dedicated to CAPR is 0.00%, an increase of 21.00%. Total shares owned by institutions increased in the last three months by 9.74% to 2,941K shares. CAPR / Capricor Therapeutics Inc Put/Call Ratios The put/call ratio of CAPR is 0.31, indicating a bullish outlook.

What are Other Shareholders Doing?

CAPR / Capricor Therapeutics Inc Shares Held by Institutions

VTSMX - Vanguard Total Stock Market Index Fund Investor Shares holds 767K shares representing 2.50% ownership of the company. No change in the last quarter.

VEXMX - Vanguard Extended Market Index Fund Investor Shares holds 336K shares representing 1.09% ownership of the company. In it's prior filing, the firm reported owning 340K shares, representing a decrease of 1.38%. The firm increased its portfolio allocation in CAPR by 6.59% over the last quarter.

Geode Capital Management holds 298K shares representing 0.97% ownership of the company. In it's prior filing, the firm reported owning 232K shares, representing an increase of 22.34%. The firm increased its portfolio allocation in CAPR by 31.98% over the last quarter.

FSMAX - Fidelity Extended Market Index Fund holds 137K shares representing 0.44% ownership of the company. In it's prior filing, the firm reported owning 114K shares, representing an increase of 16.45%. The firm increased its portfolio allocation in CAPR by 55.13% over the last quarter.

Northern Trust holds 106K shares representing 0.34% ownership of the company. In it's prior filing, the firm reported owning 106K shares, representing a decrease of 0.44%. The firm increased its portfolio allocation in CAPR by 192.76% over the last quarter.

Capricor Therapeutics Background Information
(This description is provided by the company.)

Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy and the cytokine storm associated with COVID-19. Capricor is also investigating the field of extracellular vesicles and exploring the potential of exosome-based candidates to treat or prevent a variety of disorders. We are now developing two potential vaccines for COVID-19 as part of our exosome platform.

Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.

Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.

Click to Learn More

This story originally appeared on Fintel.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.